Advertisement

pp 1-23 | Cite as

The Use of Botulinum Toxin in the Management of Headache Disorders

  • Hsiangkuo Yuan
  • Stephen D. SilbersteinEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

Tremendous progress has been made in the past decades for the treatment of headache disorders. Chronic migraine is the most disabling type of headache and requires the use of acute and preventive medications, many of which are associated with adverse events that limit patient adherence. Botulinum toxin (BoNT) serotype A, a neurotoxin derived from certain strains of Clostridium, disrupts neuropeptide secretion and receptor translocation related to trigeminal nociception, thereby preventing pain sensitization through peripheral and possibly central mechanisms. Ever since the first randomized controlled trial on onabotulinumtoxinA (onabotA) for migraine was published two decades ago, onabotA has been the only BoNT formulation approved for use in the prevention of chronic migraine. Superior tolerability and efficacy have been demonstrated on multiple migraine endpoints in many controlled trials and real-life studies. OnabotA is a safe and efficacious treatment for chronic migraine and possibly high-frequency episodic migraine. Further research is still needed to understand its mechanism of action to fully develop its therapeutic potential.

Keywords

Botulinum toxin Calcitonin gene-related peptide Migraine 

Notes

Acknowledgments

Disclosure: Dr. Yuan received honoraria from Supernus Pharmaceuticals, Inc. Dr. Silberstein is a consultant and/or advisory panel member for and has receives honoraria from Alder (Lundbeck) Biopharmaceuticals; Allergan, Inc.; Amgen; Biohaven; Cefaly; Curelator; eNeura Inc.; electroCore Medical, LLC; Impel NeuroPharma; Medscape, LLC; Novartis; Ipsen Biopharmaceuticals; Eli Lilly, MedscapevLLC; Satsuma; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals and Trigemina, Inc. No funding was received for this manuscript.

References

  1. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35:563–578Google Scholar
  2. Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P, Investigators RP (2019a) An open-label prospective study of the real-life use of on a botulinum toxin A for the treatment of chronic migraine: the REPOSE study. J Headache Pain 20:26Google Scholar
  3. Ahmed F, Buture A, Tanvir T, Khalil M (2019b) Medication overuse does not affect response to OnabotulinumtoxinA treatment in patients with Chronic Migraine; update from real-life data from Hull Headache Clinic. In: Paper presented at the international headache congress. Dublin, Ireland, September 5–8, pp IHC-PO-397Google Scholar
  4. Ahmed F, Buture A, Tanvir T, Khalil M (2019c) Analysis of patterns of response to OnabotulinumtoxinA in Chronic Migraine in predicting long-term outcome. In: Paper presented at the International Headache Congress. Dublin, Ireland, September 5–8, pp IHC-PO-398Google Scholar
  5. Aicua-Rapun I, Martinez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL (2016) Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin a during more than one year. J Headache Pain 17:112Google Scholar
  6. Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P (2019) Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol 26:1464–1470Google Scholar
  7. Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P (2020) Short and mid-term predictors of response to OnabotulinumtoxinA: real-life experience observational study. Headache 60:677–685Google Scholar
  8. American Headache Society (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. Headache 59:1–18Google Scholar
  9. Antonucci F, Corradini I, Fossati G, Tomasoni R, Menna E, Matteoli M (2016) SNAP-25, a known presynaptic protein with emerging postsynaptic functions. Front Synaptic Neurosci 8:7Google Scholar
  10. Armanious M, Jimenez-Sanders R (2019) A retrospective analysis to evaluate the response of the addition of erenumab to onabotulinumtoxinA for the prevention of intractable chronic migraine without aura. In: Paper presented at the AHS 61st annual scientific meeting. Philadelphia, USA, July 11–14, pp P226LBGoogle Scholar
  11. Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, Raicher I, Uceyler N, Sommer C, Bouhassira D (2016) Safety and efficacy of repeated injections of botulinum toxin in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 15:555–565Google Scholar
  12. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803Google Scholar
  13. Barash JR, Arnon SS (2014) A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 209:183–191Google Scholar
  14. Black JD, Dolly JO (1986) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 103:535–544Google Scholar
  15. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, Camilli PD, Südhof TC, Niemann H, Jahn R (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365:160–163Google Scholar
  16. Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K (2002) Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205:59–63Google Scholar
  17. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13:361–378Google Scholar
  18. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A (2003) Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 43:884–891Google Scholar
  19. Blumenfeld AM, Schim JD, Chippendale TJ (2008) Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 48:210–220Google Scholar
  20. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418Google Scholar
  21. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ (2017) Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache 57:766–777Google Scholar
  22. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA (2018) Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19:13Google Scholar
  23. Blumenfeld AM, Tepper SJ, Robbins LD, Manack Adams A, Buse DC, Orejudos A, Silberstein DS (2019) Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry 90:353–360Google Scholar
  24. Boudreau GP, Catherine D (2019) Treatment of chronic migraine with erenumab alone or as an add on therapy; a real world prospective observational study. Paper presented at the International Headache Congress. Dublin, Ireland, September 5–8, pp IHC-OR-025Google Scholar
  25. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C (2002) Botox post-stroke spasticity study G. intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347:395–400Google Scholar
  26. Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B (2019) Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg 143:239–250Google Scholar
  27. Bumb A, Seifert B, Wetzel S, Agosti R (2013) Patients profiling for Botox(R) (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker. Springerplus 2:377Google Scholar
  28. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34:853–869Google Scholar
  29. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428–432Google Scholar
  30. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU (2011) A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 51:21–32Google Scholar
  31. Cai BB, Francis J, Brin MF, Broide RS (2017) Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection. Neuroscience 352:155–169Google Scholar
  32. Caleo M, Spinelli M, Colosimo F, Matak I, Rossetto O, Lackovic Z, Restani L (2018) Transynaptic action of botulinum neurotoxin type a at central cholinergic Boutons. J Neurosci 38:10329–10337Google Scholar
  33. Cernuda-Morollon E, Martinez-Camblor P, Ramon C, Larrosa D, Serrano-Pertierra E, Pascual J (2014) CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 54:987–995Google Scholar
  34. Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J (2015) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia 35:864–868Google Scholar
  35. Colasante C, Rossetto O, Morbiato L, Pirazzini M, Molgo J, Montecucco C (2013) Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol 48:120–127Google Scholar
  36. Connan C, Popoff MR (2017) Uptake of Clostridial neurotoxins into cells and dissemination. In: Barth H (ed) Uptake and trafficking of protein toxins. Springer, Basel, pp 39–78Google Scholar
  37. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125–133Google Scholar
  38. Delnooz CC, Pasman JW, Beckmann CF, van de Warrenburg BP (2013) Task-free functional MRI in cervical dystonia reveals multi-network changes that partially normalize with botulinum toxin. PLoS One 8:e62877Google Scholar
  39. Delnooz CC, Pasman JW, van de Warrenburg BP (2015) Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia. Neurobiol Dis 73:327–333Google Scholar
  40. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, Group PCMS (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814Google Scholar
  41. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, Group PCMS (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936Google Scholar
  42. Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, Lipton RB (2016) Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 56:821–834Google Scholar
  43. Dominguez C, Pozo-Rosich P, Torres-Ferrus M, Hernandez-Beltran N, Jurado-Cobo C, Gonzalez-Oria C, Santos S, Monzon MJ, Latorre G, Alvaro LC, Gago A, Gallego M, Medrano V, Huerta M, Garcia-Alhama J, Belvis R, Leira Y, Leira R (2018) On a botulinum toxin A in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol 25:411–416Google Scholar
  44. Drinovac Vlah V, Bach-Rojecky L, Lackovic Z (2016) Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain. J Neural Transm (Vienna) 123:1403–1413Google Scholar
  45. Drinovac V, Bach-Rojecky L, Matak I, Lackovic Z (2013) Involvement of mu-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 70:331–337Google Scholar
  46. Drinovac V, Bach-Rojecky L, Lackovic Z (2014) Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J Neural Transm (Vienna) 121:665–669Google Scholar
  47. Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35–42; discussion 42-33Google Scholar
  48. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW (2005) Duration of migraine is a predictor for response to botulinum toxin type A. Headache 45:308–314Google Scholar
  49. Ferrari A, Manca M, Tugnoli V, Alberto L (2018) Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol 33:7–18Google Scholar
  50. Filipovic B, Matak I, Bach-Rojecky L, Lackovic Z (2012) Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One 7:e29803Google Scholar
  51. Freund B, Rao A (2019) Efficacy of botulinum toxin in tension-type headaches: a systematic review of the literature. Pain Pract 19:541–551Google Scholar
  52. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–69Google Scholar
  53. GBD 2016 DALYs Hale Collaborators (2017) Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1260–1344Google Scholar
  54. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259Google Scholar
  55. Gerona RR, Larsen EC, Kowalchyk JA, Martin TF (2000) The C terminus of SNAP25 is essential for Ca(2+)-dependent binding of synaptotagmin to SNARE complexes. J Biol Chem 275:6328–6336Google Scholar
  56. Ghosal KJ, Patel K, Singh BR, Hale ML (2018) Role of critical elements in botulinum neurotoxin complex in toxin routing across intestinal and bronchial barriers. PLoS One 13:e0199524Google Scholar
  57. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:553–622Google Scholar
  58. Gu S, Jin R (2013) Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol 364:21–44Google Scholar
  59. Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA (2017) Long-term treatment benefits and prolonged efficacy of OnabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol 8:586Google Scholar
  60. Hallett M (2018) Mechanism of action of botulinum neurotoxin: unexpected consequences. Toxicon 147:73–76Google Scholar
  61. Harper CB, Papadopulos A, Martin S, Matthews DR, Morgan GP, Nguyen TH, Wang T, Nair D, Choquet D, Meunier FA (2016) Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles. Sci Rep 6:19654Google Scholar
  62. Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211Google Scholar
  63. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:470–485Google Scholar
  64. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ (2019) Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open 9:e027953Google Scholar
  65. Hong B, Yao L, Ni L, Wang L, Hu X (2017) Antinociceptive effect of botulinum toxin A involves alterations in AMPA receptor expression and glutamate release in spinal dorsal horn neurons. Neuroscience 357:197–207Google Scholar
  66. Hubbard CS, Becerra L, Smith JH, DeLange JM, Smith RM, Black DF, Welker KM, Burstein R, Cutrer FM, Borsook D (2016) Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal. Front Hum Neurosci 10:497Google Scholar
  67. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R (2006) Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 125:286–295Google Scholar
  68. Jurasinski CV, Lieth E, Dang Do AN, Schengrund C-L (2001) Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon 39:1309–1315Google Scholar
  69. Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, Karst M, Dressler D (2016) Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna) 123:533–540Google Scholar
  70. Kosaras B, Jakubowski M, Kainz V, Burstein R (2009) Sensory innervation of the calvarial bones of the mouse. J Comp Neurol 515:331–348Google Scholar
  71. Lackovic Z, Filipovic B, Matak I, Helyes Z (2016) Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches. Br J Pharmacol 173:279–291Google Scholar
  72. Lazarov NE (2002) Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog Neurobiol 66:19–59Google Scholar
  73. Lee MJ, Lee C, Choi H, Chung CS (2016) Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study. J Neurol Sci 363:51–54Google Scholar
  74. Lin KH, Chen SP, Fuh JL, Wang YF, Wang SJ (2014) Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study. J Chin Med Assoc 77:10–15Google Scholar
  75. Maday S, Twelvetrees AE, Moughamian AJ, Holzbaur EL (2014) Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron 84:292–309Google Scholar
  76. Magalhaes E, Menezes C, Cardeal M, Melo A (2010) Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 112:463–466Google Scholar
  77. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB (2011) Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 76:711–718Google Scholar
  78. Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache 55:3–20Google Scholar
  79. Masters-Israilov A, Robbins MS (2019) OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache 59:1753–1761Google Scholar
  80. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z (2011) Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186:201–207Google Scholar
  81. Matak I, Rossetto O, Lackovic Z (2014) Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain 155:1516–1526Google Scholar
  82. Matak I, Bolcskei K, Bach-Rojecky L, Helyes Z (2019) Mechanisms of botulinum toxin type A action on pain. Toxins (Basel) 11:459Google Scholar
  83. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, Group BCS (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45:293–307Google Scholar
  84. Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J, Burstein R (2017) Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly Myelinated (Adelta) but not unmyelinated (C) meningeal Nociceptors. J Neurosci 37:10587–10596Google Scholar
  85. Melo-Carrillo A, Strassman AM, Schain AJ, Noseda R, Ashina S, Adams A, Brin MF, Burstein R (2019) Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia 39:1358–1365Google Scholar
  86. Messlinger K, Balcziak LK, Russo AF (2020) Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators. J Neural Transm (Vienna) 127:431–444Google Scholar
  87. Mika J, Rojewska E, Makuch W, Korostynski M, Luvisetto S, Marinelli S, Pavone F, Przewlocka B (2011) The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 175:358–366Google Scholar
  88. Naumann M, Yakovleff A, Durif F, Group BCDPS (2002) A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249:57–63Google Scholar
  89. Negro A, Curto M, Lionetto L, Martelletti P (2015a) A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain 17:1Google Scholar
  90. Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P (2015b) OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus 4:826Google Scholar
  91. Paterson K, Lolignier S, Wood JN, McMahon SB, Bennett DL (2014) Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann Neurol 75:591–596Google Scholar
  92. Pellett S, Tepp WH, Scherf JM, Johnson EA (2015) Botulinum neurotoxins can enter cultured neurons independent of synaptic vesicle recycling. PLoS One 10:e0133737Google Scholar
  93. Pirazzini M, Rossetto O, Bertasio C, Bordin F, Shone CC, Binz T, Montecucco C (2013) Time course and temperature dependence of the membrane translocation of tetanus and botulinum neurotoxins C and D in neurons. Biochem Biophys Res Commun 430:38–42Google Scholar
  94. Relja M, Miletic V (2017) When movement disorders hurt: addressing pain in hyperkinetic disorders. Parkinsonism Relat Disord 44:110–113Google Scholar
  95. Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M (2011) Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 31:15650–15659Google Scholar
  96. Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, Rossetto O, Caleo M, Schiavo G (2012) Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 8:e1003087Google Scholar
  97. Rheaume C, Cai BB, Wang J, Fernandez-Salas E, Aoki KR, Francis J, Broide RS (2015) A highly specific monoclonal antibody for botulinum neurotoxin type A-cleaved SNAP25. Toxins (Basel) 7:2354–2370Google Scholar
  98. Rummel A (2015) The long journey of botulinum neurotoxins into the synapse. Toxicon 107:9–24Google Scholar
  99. Rummel A (2017) Two feet on the membrane: uptake of clostridial neurotoxins. In: Barth H (ed) Uptake and trafficking of protein toxins. Springer, Basel, pp 1–37Google Scholar
  100. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 12:427–433Google Scholar
  101. Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A (2019) Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact Onabotulinumtoxin-A treatment. Front Neurol 10:678Google Scholar
  102. Schueler M, Neuhuber WL, De Col R, Messlinger K (2014) Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents. Headache 54:996–1009Google Scholar
  103. Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, Kuroi T, Ebine T, Koizumi K, Suzuki N (2012) Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 48:367–378Google Scholar
  104. Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. For the BOTOX migraine clinical research group. Headache 40:445–450Google Scholar
  105. Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC (2015) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 86:996–1001Google Scholar
  106. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA (2016) Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development Subcommittee of the American Academy of neurology. Neurology 86:1818–1826Google Scholar
  107. Solomon M, Nahas SJ, Segal JZ, Young WB (2011) Medication adaptation headache. Cephalalgia 31:515–517Google Scholar
  108. Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R (2019) Real-world effectiveness of on a botulinum toxin A treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. J Headache Pain 20:81Google Scholar
  109. Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, Manack A, Proskorovsky I, Gladstone J, Buse DC, Varon SF, Goadsby PJ, Blumenfeld AM (2011) Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 51:1058–1077Google Scholar
  110. Toth S, Brueggmann EE, Oyler GA, Smith LA, Hines HB, Ahmed SA (2012) Tyrosine phosphorylation of botulinum neurotoxin protease domains. Front Pharmacol 3:102Google Scholar
  111. Tsai YC, Kotiya A, Kiris E, Yang M, Bavari S, Tessarollo L, Oyler GA, Weissman AM (2017) Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci USA 114:E5158–E5166Google Scholar
  112. Verderio C, Grumelli C, Raiteri L, Coco S, Paluzzi S, Caccin P, Rossetto O, Bonanno G, Montecucco C, Matteoli M (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8:142–153Google Scholar
  113. Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, Auff E, Schnider P (2003) A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61:940–944Google Scholar
  114. Vollesen AL, Benemei S, Cortese F, Labastida-Ramirez A, Marchese F, Pellesi L, Romoli M, Ashina M, Lampl C (2018) School of advanced studies of the European headache F. Migraine and cluster headache - the common link. J Headache Pain 19:89Google Scholar
  115. Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM, Finn DP, Wheeler L, Dolly JO (2011) A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 286:6375–6385Google Scholar
  116. Weise D, Weise CM, Naumann M (2019) Central effects of botulinum neurotoxin-evidence from human studies. Toxins (Basel):11Google Scholar
  117. Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245–258Google Scholar
  118. Silberstein SD, Lipton RB, Dodick DW (eds) (2007) Wolff’s headache and other head pain, 8th edn. Oxford University Press, New YorkGoogle Scholar
  119. Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM (2019) Effects of on a botulinum toxin A treatment in patients with and without allodynia: results of the COMPEL study. J Headache Pain 20:10Google Scholar
  120. Yuan H, Baggaley S, Ozudogru S, Digre K (2019) CGRP antibodies as adjunctive prophylactic therapy for prolonging the therapeutic effect of OnabotulinumtoxinA injections among chronic migraine patients. In: Paper presented at the AHS 61st annual scientific meeting. Philadelphia, USA, July 11–14, pp P09Google Scholar
  121. Zhang X, Strassman AM, Novack V, Brin MF, Burstein R (2016) Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia 36:875–886Google Scholar
  122. Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita SI, Martinez-Carranza M, Dong M, Stenmark P (2017) Identification and characterization of a novel botulinum neurotoxin. Nat Commun 8:14130Google Scholar
  123. Zidan A, Roe C, Burke D, Mejico L (2019) OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. J Clin Neurosci 69:237–240Google Scholar
  124. Zychowska M, Rojewska E, Makuch W, Luvisetto S, Pavone F, Marinelli S, Przewlocka B, Mika J (2016) Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain. Eur J Pharmacol 791:377–388Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Jefferson Headache CenterThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations